|
|
|
Guest co-host Anna Rose Welch of Advancing RNA fame joins us on this week’s Business of Biotech podcast for a conversation with the leaders of RNA upstart Radar Therapeutics. The company’s co-founders, Eerik Kaseniit, Ph.D. (CSO & President) and Sophia Lugo (CEO), are making waves in the mRNA therapeutics space on the heels of the invention of a precision-expressed mRNA technology that laid bare the path to Radar’s inception. |
|
|
|
|
|
| Formulating Polymer Nanoparticles | Application Note | By R. Markewicz, H. Scott, E. Klavon, et al., Helix Biotech | Researchers working with PNP's to provide efficient and targeted treatments are facing challenges with scaling-up manufacturing and production. |
|
|
| Addressing The Challenge Of Poor Aqueous Solubility | Article | Nanoform | As pharma companies aim to overcome development obstacles, it is important to incorporate GMP expertise alongside novel technologies that can enhance the properties of APIs and dosage forms. |
|
|
|
| Process Chemicals For RNA Drug Manufacturing | Brochure | MilliporeSigma | Make use of our portfolio of raw materials required for mRNA with an integrated offering for all process steps, from plasmid DNA (pDNA) to mRNA synthesis to final formulation. |
|
|
|
|
By Jie Huang, MD, Ph.D., CSTEAM-Biotech | Bridge RNAs are structured noncoding RNAs that facilitate programmable recombination between target and donor DNA, enabling precise genomic rearrangements. A significant advantage is their modularity. |
|
|
|
Linear mRNA analytical development has been rapidly advancing in the past few years. Advancing RNA LIVE panelist Khaled Yamout outlines some of the biggest changes we’ve seen in the linear mRNA analytical paradigm, as well as the shifts he’s seen in the first three editions of USP’s guidelines for mRNA-LNP analytical development. |
|
|
.png){kind=logo}
